Prague, Czechia

Milos Beran

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Spofa United Pharmaceutical Works. Active years: 1980.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1980

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Milos Beran: Innovator in Pharmaceutical Chemistry

Introduction

Milos Beran is a notable inventor based in Prague, Czech Republic. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative patent work. His research focuses on the development of novel compounds with enhanced therapeutic properties.

Latest Patents

Milos Beran holds a patent for D-6-allyl-8-ergol-I-ylacetamide. This patent describes a process for the preparation of novel 6-substituted derivatives of D-8-ergolin-I-ylacetamide and the pharmaceutically acceptable addition salts thereof. The described composition evidences superior antilactation and antinidation characteristics compared to prior art compounds. He has 1 patent to his name, showcasing his expertise in this specialized area.

Career Highlights

Throughout his career, Milos Beran has worked with prominent organizations such as Spofa United Pharmaceutical Works and Czech Technical University in Prague. His experience in these institutions has allowed him to develop and refine his innovative ideas in pharmaceutical research.

Collaborations

Milos has collaborated with notable colleagues, including Jiri Krepelka and Miroslav Semonsky. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Milos Beran is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in the field. His innovative patent and collaborations highlight his commitment to improving therapeutic options.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…